Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Bismuth Subsalicylate: adverse event reports

All products with this active ingredient · no approved product with exactly this set

61reports naming this ingredient, 2012–20260% of all reports · about 4 a year
6reports, 12 months to March 20263 in the 12 months before
48.3%classed serious, as reportedof 60 reports stating it
21.3%record death or euthanasia, as reported13 reports
90.2%of reports concern dogs0% of all dog reports

61 adverse event reports in FDA's database list a drug whose active ingredient is recorded as bismuth subsalicylate. The earliest was received in April 2012, the latest in February 2026. No FDA-approved product has exactly this set of ingredients; the ingredient field of a report can be incomplete.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 6 reports named it, up 100% from 3 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 4 reports a year and 0% of all 1,357,245 reports (0% of all dog reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

The signs named most often are vomiting (42.6%), diarrhoea (36.1%) and lethargy (29.5%). A report can list several signs, so shares add to more than 100%; 213 different terms appear across these reports.

90.2% of reports concern dogs. Not every report describes illness: 6.6% as product or packaging defects. Of reports that state seriousness, 48.3% were classed as serious, and 21.3% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog15 · peak 1
Dec 2021: 1May 2022: 1Aug 2022: 1Nov 2022: 1Jul 2023: 1Mar 2024: 1Jun 2024: 1Jul 2024: 1Nov 2024: 1May 2025: 1Jun 2025: 1Jul 2025: 1Nov 2025: 1Jan 2026: 1Feb 2026: 12022202320242025
Cat0 · peak 1
2022202320242025
Horse0 · peak 1
2022202320242025
Other1 · peak 1
Mar 2022: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

05102012: 620122013: 520132014: 120142015: 320152016: 1020162017: 420172018: 520182019: 620192020: 520202021: 120212022: 420222023: 120232024: 420242025: 420252026: 22026

2026 covers reports received through March 2026 only.

Signs listed in reports

share of bismuth subsalicylate reports listing the termall dog reports

  1. Vomiting42.6%26
  2. Diarrhoea[diarrhea]36.1%22
  3. Lethargy[unusually tired or inactive]29.5%18
  4. Anorexia[not eating]14.8%9
  5. Death by euthanasia[the animal was euthanized]11.5%7
  6. Bloody diarrhoea[diarrhea with blood]9.8%6
  7. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]9.8%6
  8. Emesis[vomiting]9.8%6
  9. Hypoalbuminaemia[low blood albumin]9.8%6
  10. Death8.2%5
  11. Other abnormal test result NOS[abnormal laboratory result, type not specified]8.2%5
  12. Ataxia[unsteady, uncoordinated movement]6.6%4
  13. Hypoproteinaemia[low blood protein]6.6%4
  14. Leucocytosis NOS[high white blood cell count]6.6%4
  15. Anaemia NOS[low red blood cell count]4.9%3
  16. Digestive tract disorder NOS[digestive problem, type not specified]4.9%3
  17. Emesis (multiple)[vomiting more than once]4.9%3
  18. Hypokalaemia[low blood potassium]4.9%3

Top 30 of 213 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal32.8%20
Recovered with Sequela0%0
Ongoing31.1%19
Died9.8%6
Euthanized11.5%7
Outcome Unknown13.1%8

What kind of report it was

Safety issue86.9%53
Lack of expected effectiveness0%0
Both safety and lack of expected effectiveness6.6%4
Manufacturing or product defect6.6%4
Other0%0

Coloured bar: reports naming bismuth subsalicylate. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Dog90.2%55
Cat3.3%2
Ferret1.6%1
Horse1.6%1
Other Mammals1.6%1

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year11.5%7
1 to 3 years26.2%16
4 to 7 years23%14
8 to 11 years18%11
12 years and over18%11
Age not given3.3%2

Weight of the animal

Under 5 kg (11 lb)24.6%15
5 to 9.9 kg (11–22 lb)11.5%7
10 to 24.9 kg (22–55 lb)27.9%17
25 to 44.9 kg (55–99 lb)21.3%13
45 kg and over (99 lb+)9.8%6
Weight not given4.9%3

Route of administration stated in reports: oral (30).

In context

MeasureBismuth SubsalicylateAll dog reportsAll reports
Reports61985,6751,357,245
Share of that pool's reports naming this drug—0%0%
Classed serious, of reports stating it48.3%38.3%38.6%
Death or euthanasia recorded, per 1,000 reports213.15563.8
Filed as lack of expected effectiveness (wholly or partly)6.6%—23%
Top term, share of reportsVomiting 42.6%19.7%—

This set accounts for 100% of all reports naming bismuth subsalicylate, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

No approved product has exactly this set of active ingredients. The ingredient field of a report can be incomplete; these approved products contain all of the ingredients named here, together with others.

Trade nameActive ingredientsSponsorApproved forApplication
Entefur Bolus Veterinary; Entefur Powder Veterinaryapproval voluntarily withdrawnBismuth Subsalicylate, FuramazoneProctor & Gamble Pharmaceuticals, Inc.—NADA 010-158

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about bismuth subsalicylate reports

How many adverse event reports has FDA received for bismuth subsalicylate?

61 reports record a drug with bismuth subsalicylate as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 6 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

vomiting (42.6%), diarrhoea (36.1%), lethargy (29.5%), anorexia (14.8%) and death by euthanasia (11.5%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

dog (90.2%), cat (3.3%) and ferret (1.6%). Among single-breed animals the most frequent labels are Labrador Retriever, German Shepherd Dog, Pit Bull and Golden Retriever; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

6 reports in the 12 months to March 2026, up 100% from 3 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that bismuth subsalicylate harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of bismuth subsalicylate?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.